NAV

Amitraz

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Amitraz
DrugBank Accession Number
DB11373
Background

Amitraz is a non-systemic acaricide and insecticide. It was generated in 1969 by the Boots Co. in England. Amitraz presents insect repellent effects and hence, it can be used as an insecticide and pesticide. Its insecticide effect is due to its agonistic activity in the alpha-adrenergic system, its interaction with the octopamine receptors in the central nervous system and its driven inhibition of the synthesis of monoamine oxidases and prostaglandins. All the abovementioned effects are translated into the overexcitation, paralysis, and death in insects.

Amitraz presents a lower effect in mammals and thus, it is widely used in the treatment of mite- or tick-infestation of dogs.

Type
Small Molecule
Groups
Experimental, Vet approved
Structure
Similar Structures
Weight
Average: 293.406
Monoisotopic: 293.189197751
Chemical Formula
C19H23N3
Synonyms
  • 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene
  • Amitraz
  • Amitraze
  • Amitrazum
  • N,N'-(methyliminodimethylidyne)bis-2,4-xylidine
External IDs
  • U-36-059
  • U-36,059
  • U-36059
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcebutololThe therapeutic efficacy of Amitraz can be decreased when used in combination with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Amitraz.
AcemetacinThe risk or severity of hypertension can be increased when Amitraz is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Amitraz.
AclidiniumThe risk or severity of Tachycardia can be increased when Aclidinium is combined with Amitraz.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Mitac

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
33IAH5017S
CAS number
33089-61-1
InChI Key
QXAITBQSYVNQDR-ZIOPAAQOSA-N
InChI
InChI=1S/C19H23N3/c1-14-6-8-18(16(3)10-14)20-12-22(5)13-21-19-9-7-15(2)11-17(19)4/h6-13H,1-5H3/b20-12+,21-13+
IUPAC Name
(E)-N'-(2,4-dimethylphenyl)-N-[(E)-[(2,4-dimethylphenyl)imino]methyl]-N-methylmethanimidamide
SMILES
CN(\C=N\C1=C(C)C=C(C)C=C1)\C=N\C1=C(C)C=C(C)C=C1

References

General References
  1. Lee S, Kim TH, Shin YW, Jeon Y, Kim J: Amitraz. Acta Crystallogr Sect E Struct Rep Online. 2013 Jul 24;69(Pt 8):o1300. doi: 10.1107/S1600536813019764. eCollection 2013. [Article]
  2. Varma PV, Bhatt S, Bhat RY: Amitraz poisoning. Indian J Pediatr. 2013 Apr;80(4):349-50. doi: 10.1007/s12098-012-0772-2. Epub 2012 May 11. [Article]
  3. Caprotta CG, Martinez M, Tiszler M, Guerra V: [Amitraz poisoning]. Arch Argent Pediatr. 2009 Oct;107(5):456-8. doi: 10.1590/S0325-00752009000500015. [Article]
  4. Gursoy S, Kunt N, Kaygusuz K, Kafali H: Intravenous amitraz poisoning. Clin Toxicol (Phila). 2005;43(2):113-6. [Article]
  5. Aydin K, Per H, Kurtoglu S, Poyrazoglu MH, Narin N, Aslan D: Amitraz poisoning in children. Eur J Pediatr. 2002 Jun;161(6):349-50. Epub 2002 Apr 16. [Article]
  6. Yaramis A, Soker M, Bilici M: Amitraz poisoning in children. Hum Exp Toxicol. 2000 Aug;19(8):431-3. [Article]
  7. Saha T, Chatterjee S, Saha K, Chowdhury A, Somchoudhury AK, Bhattacharyya A: Residues of amitraz, a new acaricide, on tea. Bull Environ Contam Toxicol. 2000 Aug;65(2):215-21. [Article]
  8. Godara R, Parveen S, Katoch R, Yadav A, Verma PK, Katoch M, Kaur D, Ganai A, Raghuvanshi P, Singh NK: Acaricidal activity of extract of Artemisia absinthium against Rhipicephalus sanguineus of dogs. Parasitol Res. 2014 Feb;113(2):747-54. doi: 10.1007/s00436-013-3704-9. Epub 2013 Nov 28. [Article]
  9. Hepperle J, Mack D, Sigalov I, Schuler S, Anastassiades M: Analysis of "Amitraz (sum)" in pears with incurred residues - Comparison of the approach covering the individual metabolites via LC-MS/MS with the approach involving cleavage to 2,4-dimethylaniline. Food Chem. 2015 Jan 1;166:240-7. doi: 10.1016/j.foodchem.2014.06.003. Epub 2014 Jun 11. [Article]
  10. Leung VK, Chan TY, Yeung VT: Amitraz poisoning in humans. J Toxicol Clin Toxicol. 1999;37(4):513-4. [Article]
  11. Duncan KL: Treatment of amitraz toxicosis. J Am Vet Med Assoc. 1993 Oct 15;203(8):1115-6. [Article]
KEGG Drug
D02380
KEGG Compound
C10995
ChemSpider
33405
RxNav
17763
ChEBI
2665
ChEMBL
CHEMBL1365675
ZINC
ZINC000100025258
Wikipedia
Amitraz

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000647 mg/mLALOGPS
logP4.42ALOGPS
logP5.41Chemaxon
logS-5.7ALOGPS
pKa (Strongest Basic)8.83Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area27.96 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity98 m3·mol-1Chemaxon
Polarizability35.7 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dl-0950000000-fafa01247578acdffbfd
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0190000000-500d7ab9a71839e751e2
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0c0u-0920000000-74f1cd0cab5a05e5095f
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0590000000-0ca33c86b4cd80b3242f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ac3-3900000000-d9e3a5794c92140f5608
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0159-1910000000-1b5249fee344627a5c89
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-162.1915399
predicted
DarkChem Lite v0.1.0
[M-H]-160.6216399
predicted
DarkChem Lite v0.1.0
[M-H]-180.33617
predicted
DeepCCS 1.0 (2019)
[M+H]+162.7820399
predicted
DarkChem Lite v0.1.0
[M+H]+161.9417399
predicted
DarkChem Lite v0.1.0
[M+H]+182.69417
predicted
DeepCCS 1.0 (2019)
[M+Na]+162.1491399
predicted
DarkChem Lite v0.1.0
[M+Na]+160.6929399
predicted
DarkChem Lite v0.1.0
[M+Na]+189.6764
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:14 / Updated at February 21, 2021 18:53